Navigation Links
Rx for Africa, Inc. to Benefit from New Ethiopian Government Policy on Pharma Industry
Date:1/31/2008

Local Production to be Favored

ADDIS ABABA, Ethiopia, Jan. 31 /PRNewswire-FirstCall/ -- Rx Africa (Ethiopia) PLC, the wholly-owned generic drug manufacturing subsidiary of Rx for Africa, Inc. (Pink Sheets: RXAF), is positioned to benefit greatly from powerful new incentives for Ethiopia's local pharmaceutical industry put into place by the Federal Government of Ethiopia.

"We applaud the Ethiopian government for its visionary support of our burgeoning industry. The health of Ethiopian citizens and economy, and the health of our own company, Rx Africa (Ethiopia) PLC, will benefit for years to come," said Dr. Mulugetta Bezzabeh, Chairman of Rx for Africa, Inc.

Dr. Bezzabeh continued, "Over the next year, we will launch over 35 new products, many in high demand by the government for clinics and hospitals. We welcome the opportunity to bid for these contracts under the new policies that give locally manufactured pharmaceuticals first priority. Last year the government purchased US $400 million of medications, and this amount is growing.

"Because local manufacturers will also receive up to ten years tax holiday for special investments in pharmaceuticals, and no tax on locally produced pharmaceuticals for export, our ability to invest in capital projects is greatly increased, enabling us to complete our upgrades sooner. We will also benefit by the Federal Government Investment Commission's new directive in which all technologies for manufacturing and for R&D activities will be exempt from paying duty and related taxes.

"To further promote the local industry, the government has placed a tariff ranging from 15-30% on pharmaceutical imports and the Federal Drug Authority of Ethiopia has issued new directives preventing the import of drugs that are similar to those that are produced in sufficient quantity in Ethiopia. The Authority has outright banned 120 Asian importing companies for supplying counterfeit or sub-standard medications. This is of enormous help to us, as well. We will be more productive under these favorable conditions."

Forward Looking Statements

This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward-looking statements involve known and unknown risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's partners or others that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.


'/>"/>
SOURCE Rx for Africa, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. AIDS Remains Leading Cause of Death in Africa, According to UN
2. Antioxidants show no clear benefit against cardiovascular events, death in high-risk women
3. Ambulatory oxygen rarely a benefit in COPD patients without resting hypoxemia
4. Discovery of sugar sensor in intestine could benefit diabetes
5. Study shines more light on benefit of vitamin D in fighting cancer
6. Vitamin Es lack of heart benefit linked to dosage
7. Practice-based intervention has sustained benefits for children and families
8. Manic phase of bipolar disorder benefits from breast cancer medication
9. Medicare Prescription Drug Benefit, Nonprofit Hospitals, Ambulatory Surgery Centers, Statistical Methods, and Pay-For-Performance Highlighted In the Latest INQUIRY Journal
10. Scientists highlight benefits of genetic research in sport, but warn of ethical concerns
11. The Butterfly Ball to Benefit Lung Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... WHAT: ... networking and recognition opportunities as well as advocacy for the state and region‘s ... on February 23. The Council's Innovation Forecast event highlights innovation throughout the ...
(Date:2/24/2017)... ... , ... With millions of Americans and people worldwide struggling ... are aware of our options and are empowered with strength and information throughout ... its newest edition of "Vision and Hearing" in USA Today, that will educate ...
(Date:2/24/2017)... , ... February 24, 2017 , ... Yisrayl Hawkins, Pastor ... on Bible Prophecy concerning this present generation. Yisrayl makes an astounding statement when ... generation. He explains that the Bible details the current times so plainly that ...
(Date:2/24/2017)... ... February 24, 2017 , ... Congratulations to ... Elite division on February 12th. Ms. Esparza qualified into this prestigious status ... competition held in Las Vegas, Nevada. Frida is one of approximately 25 gymnasts ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... to funding innovative lymphoma research and serving the lymphoma community through a comprehensive ... the La Gorce Country Club in Miami Beach to host its Swirl: Miami ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... YORK , Feb. 23, 2017  The ... 330.6 million by 2021 from USD 275.9 million ... Read the full report: http://www.reportlinker.com/p04718602-summary/view-report.html ... increasing spending on pharmaceutical R&D, and growth in ... driving the market growth for particle counters. On ...
(Date:2/23/2017)... , Feb 23, 2017 Research and Markets ... Price Analysis and Strategies - 2016" report to their offering. ... The latest ... provides drug pricing data and benchmarks in the global Autism Spectrum ... What are the key drugs marketed for Autism ...
(Date:2/23/2017)... CITY, Calif., Feb. 23, 2017 Nevro Corp. (NYSE: ... evidence-based solutions for the treatment of chronic pain, today reported ... December 31, 2016. 2016 Accomplishment & Highlights: ... full year 2016, an increase of 228% as reported, over ... for 2016, an increase of 612% over the prior year ...
Breaking Medicine Technology: